Annual General Meeting 2025: Resolutions and Strategy
The Annual General Meeting of Evotec SE on June 3, 2025, provided significant insights into the strategic direction of the company. Here is an overview of the key topics:
Agenda Items and Resolutions
All submitted agenda items received a clear majority. This included the discharge of the Management Board and Supervisory Board for the financial year 2024, approval of the compensation report, and adjustments to the Share Performance Plan 2022.
Strategic Outlook
CEO Dr. Christian Wojczewski presented the future strategy of the company with a clear focus on innovation and expertise in drug research.
New Board Members
Two new leaders were introduced, Aurélie Dalbiez as Chief People Officer and Paul Hitchin as Chief Financial Officer.
Virtual Annual General Meetings
The articles of association of Evotec were amended to allow for virtual annual general meetings, thereby enabling a more flexible response to future challenges.
Auditor Confirmation
BDO AG was confirmed as the auditor for the year 2025.
Market Environment and Outlook
In a challenging market environment, Evotec plans strategic adjustments to continue growing and fostering innovation. The shares of Evotec are trading between 6.93 euros and 7.11 euros, with a market capitalization of around 1.2 billion euros. Analysts remain optimistic and continue to recommend the stock for purchase. Notable progress has been made in the research, particularly with the new NLRP3 inflammasome inhibitors, which could provide significant medical and economic impulses.
Overall, significant strategic decisions were made at the Annual General Meeting 2025, enabling Evotec SE to successfully adapt to changing market conditions and further enhance its position as a leading company in drug research.